Eli Lilly and Company (LLY)vsSerina Therapeutics Inc (SER)
LLY
Eli Lilly and Company
$851.21
+9.80%
HEALTHCARE · Cap: $760.43B
SER
Serina Therapeutics Inc
$1.83
-1.08%
HEALTHCARE · Cap: $27.26M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 50137593% more annual revenue ($65.18B vs $130,000). LLY leads profitability with a 31.7% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
SER
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
-24.8%
Fair Value
$1.49
Current Price
$1.83
$0.34 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Revenue surging 154.9% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 28.7x book value
Smaller company, higher risk/reward
0.0% margin — thin
Elevated debt levels
ROE of -8159.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bull Case : SER
The strongest argument for SER centers on Revenue Growth. Revenue growth of 154.9% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : SER
The primary concerns for SER are Market Cap, Profit Margin, Debt/Equity. Debt-to-equity of 1.82 is elevated, increasing financial risk.
Key Dynamics to Monitor
LLY profiles as a growth stock while SER is a hypergrowth play — different risk/reward profiles.
LLY carries more volatility with a beta of 0.50 — expect wider price swings.
SER is growing revenue faster at 154.9% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 21/100), backed by strong 31.7% margins and 42.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Serina Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Serina Therapeutics Inc is an innovative biotechnology firm dedicated to addressing unmet medical needs in oncology and neurology through its proprietary polymer-based drug delivery platform. This advanced technology enhances the efficacy of therapies, significantly improving patient outcomes while positioning the company for sustainable growth in the competitive biopharmaceutical landscape. With a robust pipeline of product candidates and strategic collaborations, Serina is poised to transform healthcare solutions, underscoring its commitment to delivering value for investors and advancing therapeutic possibilities.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?